Pfizer Goes Big On Generic Injectables With Acquisition Of 15 Products From India’s Claris
This article was originally published in PharmAsia News
Executive Summary
AHMEDABAD, India - Two months after Pfizer signed a comprehensive in-licensing agreement for more than 50 oral and injectable products with Aurobindo Pharma, the U.S. company has entered into another deal, with India's Claris Lifesciences, to commercialize 15 products covering a broad range of therapeutic areas including anti-infectives and pain drugs